{"id":"olanzapine-samidorphan","safety":{"commonSideEffects":[{"rate":"null","effect":"Weight gain"},{"rate":"null","effect":"Dizziness"},{"rate":"null","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL3989694","moleculeType":"Small molecule","molecularWeight":"718.83"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Olanzapine is a serotonin-dopamine antagonist that blocks the action of dopamine and serotonin in the brain, reducing psychotic symptoms. Samidorphan is a mu-opioid receptor antagonist that blocks the action of opioids, leading to weight loss.","oneSentence":"Olanzapine-samidorphan is an atypical antipsychotic that combines the antipsychotic effects of olanzapine with the weight loss effects of samidorphan.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:56.469Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of schizophrenia"}]},"trialDetails":[{"nctId":"NCT04987229","phase":"PHASE3","title":"Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects","status":"ENROLLING_BY_INVITATION","sponsor":"Alkermes, Inc.","startDate":"2021-10-22","conditions":"Bipolar I Disorder, Schizophrenia","enrollment":236},{"nctId":"NCT05303064","phase":"PHASE3","title":"Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder","status":"RECRUITING","sponsor":"Alkermes, Inc.","startDate":"2022-06-30","conditions":"Schizophrenia, Bipolar I Disorder","enrollment":220},{"nctId":"NCT01246765","phase":"","title":"National Pregnancy Registry for Psychiatric Medications","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2008-11","conditions":"Pregnant Women, Psychotropic Drugs","enrollment":5000},{"nctId":"NCT06740890","phase":"PHASE4","title":"Exercise and Olanzapine-samidorphan","status":"RECRUITING","sponsor":"New York State Psychiatric Institute","startDate":"2025-06-26","conditions":"Schizophenia Disorder, Schizoaffective Disorder, Bipolar Disorder I or II","enrollment":30},{"nctId":"NCT06649214","phase":"PHASE3","title":"A Study of Olanzapine-Samidorphan Tablets in Adults With Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2024-11","conditions":"Schizophrenia","enrollment":654},{"nctId":"NCT03201757","phase":"PHASE3","title":"Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2017-06-15","conditions":"Schizophrenia, Schizophreniform Disorder, Bipolar I Disorder","enrollment":523},{"nctId":"NCT04987658","phase":"PHASE1","title":"Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I Disorder","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2021-07-22","conditions":"Bipolar I Disorder","enrollment":7},{"nctId":"NCT05547100","phase":"PHASE1","title":"Study of the Breast Milk Pharmacokinetics of Olanzapine and Samidorphan","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2022-09-14","conditions":"Focus of Study is on Healthy Lactating Women","enrollment":12},{"nctId":"NCT03187769","phase":"PHASE3","title":"Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2017-06-08","conditions":"Schizophrenia, Schizophreniform Disorders, Bipolar I Disorder","enrollment":426},{"nctId":"NCT02161718","phase":"PHASE2","title":"A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2014-05","conditions":"Schizophrenia, Alcohol Use Disorder","enrollment":300},{"nctId":"NCT01903837","phase":"PHASE2","title":"A Study of ALKS 3831 in Adults With Schizophrenia","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2013-06","conditions":"Schizophrenia","enrollment":347},{"nctId":"NCT02873208","phase":"PHASE3","title":"A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2016-08-07","conditions":"Schizophrenia","enrollment":266},{"nctId":"NCT02694328","phase":"PHASE3","title":"A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2016-03-02","conditions":"Schizophrenia","enrollment":561},{"nctId":"NCT02669758","phase":"PHASE3","title":"A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2016-01-20","conditions":"Schizophrenia","enrollment":281},{"nctId":"NCT02634346","phase":"PHASE3","title":"A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2015-12","conditions":"Schizophrenia","enrollment":403},{"nctId":"NCT02922426","phase":"PHASE1","title":"An Insulin Sensitivity Study in Healthy Subjects","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2016-09","conditions":"Healthy Volunteers","enrollment":60},{"nctId":"NCT02804568","phase":"PHASE1","title":"A Phase 1 Safety Study in Adults With Schizophrenia","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2016-06","conditions":"Schizophrenia","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Olanzapine-samidorphan；","genericName":"Olanzapine-samidorphan；","companyName":"Qilu Pharmaceutical Co., Ltd.","companyId":"qilu-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Olanzapine-samidorphan is an atypical antipsychotic that combines the antipsychotic effects of olanzapine with the weight loss effects of samidorphan. Used for Treatment of schizophrenia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}